Hologic announced a $20.6-million ($0.08 per diluted share) profit for its second-quarter earnings, a dramatic improvement compared with a $2.3-billion loss this time last year.

The company reported revenues of $418.1 million for the quarter, ending March 27, up 4 percent compared with $402.0 million during the same period last year.

"We are pleased with our performance for the second quarter of fiscal 2010," said Rob Cascella, Hologic's president and chief executive officer in a company statement.
A January $70-million cash payment from KV Pharmaceutical Company for the sale of its Gestiva assets helped Hologic's revenue, which was hurt by a $12.5-million lawsuit regarding patent infringement cases involving breast biopsy technology with Ethicon Endo-Surgery, a Johnson and Johnson company.

Breast health revenues, including Hologic's mammography, computer-aided detection, breast biopsy, MammoSite and AEG products, increased to $189.5 million compared to $180.1 million for this time last year. The company attributes the increases to service related to the increase in the installed base of Selenia full-field digital mammography systems, the new 2D/3D Selenia Dimensions product and the Eviva breast biopsy product.

Hologic also announced that it paid the last $47-million installment of a loan used to finance the Third Wave acquisition, a year ahead of schedule.

The company said it expects third quarter fiscal revenues, ending June 26, to be about $415 million to $420 million, up from $403 million for 2009's third quarter.

More Voices